Angeles Crest Highway Accident 2018, Unagi Scooter Front Wheel Loose, Noah Taylor Harry Potter, Contrast Paints Over Leadbelcher, Articles F

The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. Going by the consensus revenue estimate of $20.4 million in 2020, FATE stock is trading at 456x its RPS of $0.25, which appears to be very high. Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Fate Therapeutics reported new results for two early-stage studies testing two different types of experimental lymphoma treatments that utilize natural killer cells, a fast-emerging form of cancer immunotherapy. Export data to Excel for your own analysis. Fate Therapeutics does not currently pay a dividend. March 1, 2023|markets.businessinsider.com, February 27, 2023|americanbankingnews.com, February 23, 2023|americanbankingnews.com, February 13, 2023|markets.businessinsider.com. The data from the trials showed that eight of eleven patients being evaluated for assessment of safety and efficacy of the FT516 treatment achieved an objective response, while six of those patients achieved a complete response. 22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. Identify stocks that meet your criteria using seven unique stock screeners. Quantbot Technologies LP bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $69,000. Could 0DTE Options Be The Cause Of The Next Market Meltdown. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. Interestingly, though, if a stock has gained over the last few days, you would do better to avoid short-term bets for most stocks - although FATE stock appears to be an exception to this general observation. Fate has been focused on the oncology and immunology pipeline for multiple cancer types including myeloid leukemia, B-cell lymphoma, and multiple myeloma among others.